The Tobacco Control Program (Program) is the focal point for University of California, San Francisco (UCSF) scientists in disciplines ranging from the molecular biology of nicotine addiction through political science. These scientists combine their efforts to eradicate the use of tobacco and tobacco-induced cancer and other diseases worldwide. A strong theme is that science-driven policy and public health interventions are key to ending the tobacco epidemic, as well as biological and clinical science. The role of the tobacco industry has been an important focus. The specific scientific goals are to conduct clinical and laboratory investigations of the mechanisms of nicotine addiction;to further understand the effects of tobacco use and exposure to second-hand tobacco smoke, including genetic studies and investigations of racial and ethnic differences in measures of tobacco exposure and tobacco-related diseases;to develop and test innovative interventions for tobacco users, especially those in high-risk populations, including youth, individuals co-morbid with mental and substance abuse disorders, chronic smokers, and ethnic minorities;to provide estimates of the economic costs of tobacco use to society and the corresponding benefits of tobacco control programs;to conduct research on tobacco related policy and to continue to study the effects of the tobacco industry, both nationally and internationally, on tobacco use;and to better describe populations with high smoking rates, both in this country and internationally. Rather than being distinct areas of work, these investigations often interact with, and benefit from each other, spanning multiple disciplines. The expertise inherent of the Program membership supports the accomplishment of these goals. Tobacco Control Program work is grouped into five themes: (1) studies of nicotine and tobacco effects, metabolism and biomarkers, including second hand smoke;(2) clinical interventions;(3) the economics of tobacco control;(4) the tobacco industry;and (5) descriptive and epidemiological studies. Since the last competitive review of the Helen Diller Family Comprehensive Cancer Center (Center), the productivity of the Program has increased, new faculty have been mentored and added to the roster, and collaboration across disciplines is increasingly evident. The Program has 20% intra-programmatic and 10% inter-programmatic publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-15
Application #
8567890
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
15
Fiscal Year
2013
Total Cost
$96,485
Indirect Cost
$90,775
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Dvorak, Christopher C; Satwani, Prakash; Stieglitz, Elliot et al. (2018) Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatr Blood Cancer 65:e27034
Fan, Qi Wen; Nicolaides, Theodore P; Weiss, William A (2018) Inhibiting 4EBP1 in Glioblastoma. Clin Cancer Res 24:14-21
Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131:
Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228
Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408
Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279
Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380
Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:

Showing the most recent 10 out of 192 publications